PLSE Pulse Biosciences, Inc.

QT62

NASDAQ·Healthcare·Medical - Instruments & Supplies·USA

Latest market price

53.66

+0.75+1.43%

Overview Short InterestFilings

PLSEQT62Pulse Biosciences, Inc.·NASDAQ

Overview Short InterestFilings

53.66+1.43%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

NVST+0.45%$24.82 ICUI-0.23%$162.01 ATRC-0.09%$59.83 MMSI-0.34%$84.03 STVN-23.81%$15.04 TFX-0.04%$140.62 BLCO-0.62%$19.89 XRAY-0.76%$9.82

Snapshot

Index	—	P/E	—	EPS (ttm)	-1.17	Insider Own	—	Shs Outstand	71.32M	Perf Week	0.46%

Market Cap	3.77B	Forward P/E	—	EPS next Y	-1.25	Insider Trans	2.47%	Shs Float	13.16M	Perf Month	10.44%

Enterprise Value	3.68B	PEG	—	EPS next Q	-0.31			Short Float	22.83%	Perf Quarter	38.59%

Income	-80.00M	P/S	—	EPS this Y	—			Short Ratio	5.75	Perf Half Y	164.10%

Sales	0.00	P/B	37.73	EPS next Y	—	ROA	-69.27%	Short Interest	3.00M	Perf YTD	285.29%

Book/sh	1.40	P/C	36.99	EPS next 5Y	—	ROE	-94.42%	52W High	58.90 -8.90%	Perf Year	213.02%

Cash/sh	1.43	P/FCF	—	EPS past 3/5Y	—	ROIC	-78.14%	52W Low	12.56 327.19%	Perf 3Y	1274.03%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	-21.60%	Volatility	4.49% 6.23%	Perf 5Y	144.57%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	-7007.76%	ATR (14)	3.12	Perf 10Y	810.50%

Dividend Ex-Date	—	Quick Ratio	9.61	Sales Y/Y TTM	—	Profit Margin	-6755.78%	RSI (14)	54.61	Recom	2.33

Dividend Gr. 3/5Y	—	Current Ratio	9.63	EPS Q/Q	-28.57%	SMA20	4.18%	Beta	1.61	Target Price	60.20

Payout	0.00%	Debt/Eq	0.05	Sales Q/Q	—	SMA50	3.46%	Rel Volume	0.49	Prev Close	52.90

Employees	116	LT Debt/Eq	0.05	Earnings	Nov 05	SMA200	67.71%	Avg Volume	504.67K	Price	53.66

IPO Date	May 18, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	-16.13% -13.20%	Net Debt/EBITDA	—	Volume	249,693	Change	1.43%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-13-26	Reiterated	Mizuho Securities		$45 → $55
Oct-13-26	Reiterated	Oppenheimer	Outperform	$35 → $60
Oct-06-26	Reiterated	Canaccord Genuity	Buy	$43 → $58
Sep-23-26	Initiated	BTIG	Buy	$70
Aug-17-26	Initiated	Needham	Buy	$58
Aug-10-26	Reiterated	Mizuho Securities		$30 → $45
Aug-10-26	Reiterated	Canaccord Genuity	Buy	$32 → $43
Jul-28-26	Reiterated	Oppenheimer		$30 → $35
Jun-04-26	Initiated	Canaccord	Buy	$32
Feb-20-26	Reiterated	Oppenheimer		$22 → $30

Latest News· Times ET

Oct-29-26

Oct-29-2604:15PM

DexCom (DXCM) Surpasses Q3 Earnings and Revenue EstimatesYahoo

01:05PM

Pulse Biosciences to Present at Stifel 2026 Healthcare Conferencebusinesswire.com

Oct-25-26

Oct-25-2606:08AM

Pulse Biosciences (PLSE) Stock Still Seems Rich Against Book ValueYahoo

Oct-22-26

Oct-22-2604:05PM

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026businesswire.com

Oct-19-26

Oct-19-2606:14AM

Varex Imaging (NASDAQ:VREX) vs. Pulse Biosciences (NASDAQ:PLSE) Head to Head Reviewdefenseworld.net

Oct-17-26

Oct-17-2606:11PM

Pulse Biosciences (PLSE) Stock Fair Value Rises After Analyst Target IncreasesYahoo

Oct-14-26

Oct-14-2608:00AM

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Centergurufocus.com

Oct-10-26

Oct-10-2605:15PM

Why Pulse Biosciences (PLSE) Is Up 12.3% After Full NANOPULSE-AF Enrollment And nPulse SpotlightYahoo

Oct-09-26

Oct-09-2604:05PM

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com

Oct-08-26

Oct-08-2607:00AM

Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026businesswire.com

Oct-07-26

Oct-07-2607:00AM

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatmentbusinesswire.com

Oct-06-26

Oct-06-2606:15AM

Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Price Target of $50.20defenseworld.net

Oct-03-26

Oct-03-2603:07PM

Pulse Biosciences (PLSE) Stock Fair Value Rises After Analysts Back NsPFA DataYahoo

Sep-27-26

Sep-27-2605:16AM

Pulse Biosciences: Promising Technology, But Hard To Justify Its ValuationSeekingAlpha

Sep-23-26

Sep-23-2606:02AM

TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On WednesdayBenzinga

Company

Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	1	2	0	1	—	—	—	—	—
Gross Profit	0	-1	0	-1	—	—	—	—	—
Selling, General and Administrative Excl. Other	31	32	24	16	—	—	—	—	—
Research and Development	52	45	32	28	—	—	—	—	—
Other Operating Expense	-1	-1	0	-2	—	—	—	—	—
Operating Income	-82	-77	-56	-44	—	—	—	—	—
Interest Expense	0	0	0	1	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	4	4	3	2	—	—	—	—	—
Net Income Before Taxes	-80	-73	-54	-42	—	—	—	—	—
Income Taxes	0	0	0	0	—	—	—	—	—
Consolidated Net Income	-80	-73	-54	-42	—	—	—	—	—
Net Income From Continuing Operations	-80	-73	-54	-42	—	—	—	—	—
Net Income	-80	-73	-54	-42	—	—	—	—	—
EPS (Recurring)	-1.17	-1.08	-0.92	-0.88	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.17	-1.08	-0.92	-0.88	—	—	—	—	—
EPS (Diluted)	-1.17	-1.08	-0.92	-0.88	—	—	—	—	—
EBITDA	-79	-72	-52	-40	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	69	67	58	48	—	—	—	—	—
Market Capitalization	3,702	920	1,010	588	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Teplitsky Liane Rae	Chief Operating Officer	Sep 01 '26	Buy	49.95	1,001	50,000	4,095	Sep 02
Teplitsky Liane Rae	Chief Operating Officer	Aug 31 '26	Buy	48.80	1,024	49,971	3,094	Sep 02
Teplitsky Liane Rae	Chief Operating Officer	Aug 28 '26	Buy	48.35	1,034	49,994	2,070	Aug 28
Teplitsky Liane Rae	Chief Operating Officer	Aug 26 '26	Buy	48.23	1,036	49,971	1,036	Aug 28
DUGGAN ROBERT W	Director, 10% Owner	May 11 '26	Buy	19.69	1,320,466	25,999,976	48,370,047	May 15
LAVIOLETTE PAUL A	Chief Executive Officer	May 11 '26	Buy	19.69	30,000	590,700	15,846	May 11
Danahy Kevin Patrick	Chief Commercial Officer	Feb 18 '26	Option Exercise	1.53	5,000	7,650	48,298	Feb 23
Danahy Kevin Patrick	Chief Commercial Officer	Feb 18 '26	Sale	23.64	5,000	118,200	43,298	Feb 23
Danahy Kevin Patrick	Chief Commercial Officer	Feb 17 '26	Option Exercise	1.53	20,000	30,600	63,298	Feb 17
Danahy Kevin Patrick	Chief Commercial Officer	Feb 17 '26	Sale	23.63	20,000	472,600	43,298	Feb 17
Danahy Kevin Patrick	Chief Commercial Officer	Feb 13 '26	Sale	23.53	20,000	470,600	43,298	Feb 17
Danahy Kevin Patrick	Chief Commercial Officer	Feb 13 '26	Option Exercise	1.53	20,000	30,600	325,000	Feb 17
Danahy Kevin Patrick	Chief Commercial Officer	Feb 12 '26	Sale	23.37	20,000	467,400	43,298	Feb 17
Danahy Kevin Patrick	Chief Commercial Officer	Feb 12 '26	Option Exercise	1.53	20,000	30,600	345,000	Feb 17
Danahy Kevin Patrick	Chief Commercial Officer	Feb 11 '26	Sale	25.20	20,000	504,000	43,298	Feb 11

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.